GlassScriptPhysician profile
Justin Mark Weaver
NPI 1245868496
$5,246.98
in general payments reported to CMS, 2019-2025
25 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $950 · 2022: $741 · 2023: $915 · 2024: $1,560 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,271.76 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,059.07 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $620.25 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Radius Health, INC. | $363.39 | 2021-2025 | Tymlos |
| Abbvie INC. | $304.85 | 2021-2024 | |
| Amgen INC. | $257.60 | 2021-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $229.95 | 2021-2025 | Vaxneuvance, Vaxelis, Proquad |
| Pfizer INC. | $213.85 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.79 | 2023-2024 | |
| Abbott Laboratories | $111.12 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.01 | 2023-2024 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $84.09 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lightforce Orthodontics, INC. | $77.23 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $75.40 | 2021-2022 | |
| Organon LLC | $38.14 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $37.51 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $33.53 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $32.55 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $26.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.87 | 2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.60 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $22.51 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.76 | 2024 | Gvoke Hypopen |
| Eisai INC. | $14.72 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.